Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect

Thromb Haemost. 2014 Aug;112(2):424-5. doi: 10.1160/TH13-12-1045. Epub 2014 Apr 24.

Authors

M Morfini¹, A Batorova, G Mariani, G Auerswald, F Bernardi, G Di Minno, A Dolce, C Fede, M Giansily-Blaizot, J Ingerslev, U Martinowitz, M Napolitano, M Pinotti, J-F Schved; International FVII [IF7] and Seven Treatment Evaluation Registry [STER] Study Groups

Affiliation

¹ Massimo Morfini, Agency for Hemophilia and Regional Reference Center for Inherited Bleeding Disorders, Azienda Ospedalieriero, Universitaria Careggi, Florence, Italy, Tel.: +39 055 7947587, Fax: +39 055 7947794, E-mail: massimo.morfini@unifi.it.

PMID: 24763923
DOI: 10.1160/TH13-12-1045

No abstract available

MeSH terms

Blood Coagulation / drug effects*
Blood Coagulation Tests
Coagulants / administration & dosage
Coagulants / pharmacokinetics*
Drug Monitoring / methods
Factor VII / genetics*
Factor VII Deficiency / blood
Factor VII Deficiency / diagnosis
Factor VII Deficiency / drug therapy*
Factor VII Deficiency / genetics
Factor VIIa / administration & dosage
Factor VIIa / pharmacokinetics*
Genetic Predisposition to Disease
Heredity
Humans
Phenotype
Predictive Value of Tests
Recombinant Proteins / administration & dosage
Recombinant Proteins / pharmacokinetics
Registries
Severity of Illness Index
Treatment Outcome

Substances

Coagulants
Recombinant Proteins
Factor VII
recombinant FVIIa
Factor VIIa

Associated data

ClinicalTrials.gov/NCT01269138